Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema
AACE Endocrinology and Diabetes · 2026-07 · 13 (4) · 649-656
DOI: 10.1016/j.aed.2026.04.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift AACE Endocrinology and Diabetes, 2026-07. Verfasst von Maxim John Levy Barnett und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Jefferson-Einstein Hospital, Philadelphia, Pennsylvania. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Internal Medicine, Jefferson-Einstein Hospital, Philadelphia, Pennsylvania.
Zitieren
APA
Levy Barnett, M. J., Siqueira Tavares de Melo, M. H., & de Medeiros Rego, M. L. (2026). Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema. AACE Endocrinology and Diabetes, 13(4), 649-656. https://doi.org/10.1016/j.aed.2026.04.001
Vancouver
Levy Barnett MJ, Siqueira Tavares de Melo MH, de Medeiros Rego ML. Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema. AACE Endocrinology and Diabetes. 2026;13(4):649-656. doi:10.1016/j.aed.2026.04.001
BibTeX
@article{LevyBarnett2026,
author = {Levy Barnett, Maxim John and Siqueira Tavares de Melo, Maria Helena and de Medeiros Rego, Maria Luiza},
title = {Extending IGF-1 Receptor Inhibition Beyond Thyroid Eye Disease: A Scoping Review of Teprotumumab Administration in Pretibial Myxedema},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
volume = {13},
number = {4},
pages = {649--656},
doi = {10.1016/j.aed.2026.04.001}
}
EUVIMED